The efficacy of TP chemotherapy combined with karelizumab on the postoperative clinical status of patients with advanced ovarian cancer

To investigate the efficacy of TP (Toripalimab Plus) chemotherapy combined with karelizumab in the treatment of advanced ovarian cancer after surgery. We recruited 96 patients with advanced ovarian cancer who were admitted to our hospital between December 2019 and December 2022 with advanced ovarian cancer and treated by tumor cell reduction surgery. The patients were randomly divided into groups using a digital table, 48 each. The control group was treated with chemotherapy, while the observation group was treated with chemotherapy combined with karelizumab. We compared the two groups with regards to adverse reactions and the levels of VEGF (Vascular Endothelial Growth Factor), MMP-9 (matrixmetalloproteinase 9), CEA (A Carcinoma Embryonic Antigen), AFP (alpha-fetoprotein), CA125 (carbohydrate antigen 125), CA19-9 (carbohydrate antigen 19-9) and T lymphocytes. There was no significant difference between the two groups with regards to adverse reactions (p > 0.05); the levels of VEGF and MMP-9 in the observation group were lower. There was a significant difference between the data before and after treatment within the same group (all p < 0.05); the levels of CEA, AFP, CA125 and CA19-9 in the observation group were lower than those in the control group, with significant differences before and after treatment within the same group (p < 0.05); the levels of CD3+ (cluster of differentiation 3+) and CD4+ in the observation group were higher, while the levels of CD8+ were lower than those in the control group. There were significant differences before and after treatment in the same group (p < 0.05). The combination of karelizumab and TP chemotherapy had a significant and positive impact on postoperative patients with advanced ovarian cancer by effectively regulating immune function and the levels of tumor markers. This protocol is safe and can be selected by considering the specific situation of individual patients.

Advanced ovarian cancer; Karelizumab; TP chemotherapy; Adverse reactions; T lymphocyte subgroup

[1] DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology. 2020; 38: 3528–3537.

[2] Jiménez-Sánchez A, Cybulska P, Mager KL, Koplev S, Cast O, Couturier D, et al. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nature Genetics. 2020; 52: 582–593.

[3] Cen Y, Fang Y, Ren Y, Hong S, Lu W, Xu J. Global characterization of extrachromosomal circular DNAs in advanced high grade serous ovarian cancer. Cell Death & Disease. 2022; 13: 342.

[4] Journal of Healthcare Engineering. Retracted: synergistic effect of stereotactic radiotherapy combined with karelizumab on patients with advanced NSCLC. Journal of Healthcare Engineering. 2023; 2023: 9759218.

[5] Feng L, Yan B, Huang Y, Li L. Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer. Clinical Epigenetics. 2021; 13: 141.

[6] Kurnit KC, Fleming GF, Lengyel E. Updates and new options in advanced epithelial ovarian cancer treatment. Obstetrics & Gynecology. 2021; 137: 108–121.

[7] Marth C, Abreu MH, Andersen KK, Aro KM, de Lurdes Batarda M, Boll D, et al. Real-life data on treatment and outcomes in advanced ovarian cancer: an observational, multinational cohort study (RESPONSE trial). Cancer. 2022; 128: 3080–3089.

[8] Pietragalla A, Duranti S, Daniele G, Nero C, Ciccarone F, Lorusso D, et al. Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. Expert Opinion on Investigational Drugs. 2021; 30: 103–110.

[9] Temkin SM, Smeltzer MP, Dawkins MD, Boehmer LM, Senter L, Black DR, et al. Improving the quality of care for patients with advanced epithelial ovarian cancer: program components, implementation barriers, and recommendations. Cancer. 2022; 128: 654–664.

[10] Yoshida K, Yoshikawa N, Kitami K, Tamauchi S, Ikeda Y, Yokoi A, et al. Metabolome analysis reveals a diversity of cancer tissues in advanced epithelial ovarian cancer. Cancer Cell International. 2021; 21: 314.

[11] Shi G, Shi P, Yu Y, Xu J, Ma J, Zhang Y, et al. Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment. Molecular Therapy Oncolytics. 2021; 23: 488–500.

[12] Hudry D, Bécourt S, Scambia G, Fagotti A. Primary or interval debulking surgery in advanced ovarian cancer: a personalized decision—a literature review. Current Oncology Reports. 2022; 24: 1661–1668.

[13] Mahmood RD, Morgan RD, Edmondson RJ, Clamp AR, Jayson GC. First-line management of advanced high-grade serous ovarian cancer. Current Oncology Reports. 2020; 22: 64.

[14] Egger EK, Buchen MA, Recker F, Stope MB, Strunk H, Mustea A, et al. Predicting incomplete cytoreduction in patients with advanced ovarian cancer. Frontiers in Oncology. 2022; 12: 1060006.

[15] Palaia I, Caruso G, Di Donato V, Perniola G, Ferrazza G, Panzini E, et al. Peri-operative blood management of Jehovah’s Witnesses undergoing cytoreductive surgery for advanced ovarian cancer. Blood Transfusion. 2021. [Preprint].

[16] Laios A, Gryparis A, DeJong D, Hutson R, Theophilou G, Leach C. Predicting complete cytoreduction for advanced ovarian cancer patients using nearest-neighbor models. Journal of Ovarian Research. 2020; 13: 117.

[17] Redondo A, Oaknin A, Rubio MJ, Barretina-Ginesta M, de Juan A, Manso L, et al. Management of advanced ovarian cancer in Spain: an expert Delphi consensus. Journal of Ovarian Research. 2021; 14: 72.

[18] Shampain KL, Wasnik AP. Postneoadjuvant chemotherapy response in advanced ovarian cancer: radiological and clinical implications. Academic Radiology. 2020; 27: 958–959.

[19] Hinchcliff E, Westin SN, Herzog TJ. State of the science: contemporary front-line treatment of advanced ovarian cancer. Gynecologic Oncology. 2022; 166: 18–24.

[20] Matulonis UA. The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data. Gynecologic Oncology. 2022; 167: 401–403.

[21] Alvarez Secord A, O’Malley DM, Sood AK, Westin SN, Liu JF. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: a review. Gynecologic Oncology. 2021; 162: 482–495.

[22] Gil-Moreno A, Alonso-Alconada L, Díaz-Feijoo B, Domingo S, Vilar A, Hernández A, et al. M-TRAP: safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients. Gynecologic Oncology. 2021; 161: 681–686.

[23] Wu L, Zhu J, Yin R, Wu X, Lou G, Wang J, et al. Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. Gynecologic Oncology. 2021; 160: 175–181.

[24] Liu H, Li Y, Yao Y, Chen K, Gan J. Meta-analysis of efficacy and safety of karelizumab combined with apatinib in the treatment of advanced gastric cancer. Disease Markers. 2022; 2022: 6971717.

[25] Guo J, Guo J, Cheng B, Sun X, Zhang H, Ma J. Synergistic effect of stereotactic radiotherapy combined with karelizumab on patients with advanced NSCLC. Journal of Healthcare Engineering. 2022; 2022: 7875627.